{"schema_version":"secwatch.filing_event.v1","accession":"0000728387-25-000010","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.244648+00:00","generated_at":"2026-05-17T08:41:02.085216+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Perspective Therapeutics appoints Maya Martinez-Davis, GSK US President, to board","bullets":["Board expanded to 6; Martinez-Davis appointed as independent director effective Sept 3, 2025.","She serves on Compensation and Nominations Committees; receives $60K annual cash retainer plus 75K options (max $450K fair value) vesting over 36 months.","Martinez-Davis brings 20+ years pharma experience; currently leads GSK's US commercial business since 2019.","Her prior roles include President of biopharma Latin America at Merck KGaA and senior roles at Pfizer and Mirati board."],"urls":{"canonical":"https://secwatch.observer/filing/0000728387-25-000010","json":"https://secwatch.observer/filing/0000728387-25-000010.json","markdown":"https://secwatch.observer/filing/0000728387-25-000010.md","text":"https://secwatch.observer/filing/0000728387-25-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000072838725000010/0000728387-25-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000072838725000010/catx-20250902.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:41:02.085216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}